Expert Insights

Podcasts

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

07/08/2026

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...

Umberto Vitolo, MD, discusses...

07/08/2026

Oncology

Podcasts

How is ctDNA MRD Testing Used in Lymphoma Care?

07/06/2026

David Russler-Germain, MD, PhD

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr David Russler-Germain...

This podcast examines the...

07/06/2026

Oncology

Videos

ctDNA MRD Testing in Lymphoma: Clinical Utility and Applications

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based minimal residual disease testing is helping refine post-treatment risk stratification, detect relapse earlier, and guide more personalized treatment decisions in diffuse large B-cell lymphoma,...

Dr David Russler-Germain...

07/06/2026

Oncology

Podcasts

What Is ctDNA MRD Testing and How Does It Work?

07/06/2026

David Russler-Germain, MD, PhD

This podcast explores the principles and clinical applications of circulating ctDNA-based MRD testing in diffuse large B-cell lymphoma, including how personalized sequencing assays can detect microscopic residual disease with greater...

This podcast explores the...

07/06/2026

Oncology

Videos

ctDNA MRD Testing in Lymphoma: What It Is and How It Works

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based MRD testing enables highly sensitive, personalized detection of residual disease and is emerging as a valuable tool for assessing treatment response, predicting relapse risk, and guiding...

Dr David Russler-Germain...

07/06/2026

Oncology

Podcasts

How Are We Detecting Residual Disease in Lymphoma Today?

07/06/2026

David Russler-Germain, MD, PhD

This podcast explores the...

07/06/2026

Oncology

Videos

Detecting Residual Disease in Lymphoma: Current and Emerging Tools

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based MRD testing is emerging as a more sensitive and accurate tool than PET/CT imaging for predicting relapse risk and assessing remission in DLBCL.

Dr David Russler-Germain...

07/06/2026

Oncology

Videos

Clinical Utility of ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer

07/01/2026

Gunnar Folprecht, MD, PhD

Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...

Gunnar Folprecht, MD, PhD,...

07/01/2026

Oncology

Videos

Ten-Year Outcomes With Tisagenlecleucel Demonstrate Durable Remissions in B-Cell Lymphoma

07/01/2026

Marco Ruella, MD

Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...

Marco Ruella, MD, discusses...

07/01/2026

Oncology

Videos

When Standard Therapy Is Not Feasible in Stage III Non–Small Cell Lung Cancer

06/30/2026

Edgardo Santos, MD

Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...

Edgardo Santos, MD, reviews the...

06/30/2026

Oncology

Recent News

News

Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

07/10/2026

Stephanie Holland

Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...

Interim results from the phase...

07/10/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma

07/10/2026

Emily Estrada

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

The FDA has approved...

07/10/2026

Oncology

News

Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...

A multicenter real-world study...

07/09/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

News

Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...

Results from a multicenter...

07/09/2026

Oncology

News

Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma

07/09/2026

Stephanie Holland

Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...

Results from a phase 1 trial...

07/09/2026

Oncology

News

First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia

07/09/2026

Stephanie Holland

Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...

Results from the ongoing, phase...

07/09/2026

Oncology

News

Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis

07/09/2026

Stephanie Holland

Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...

Updated results from a post hoc...

07/09/2026

Oncology

News

Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer

07/09/2026

Emily Estrada

Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...

Results from the phase 3 PrTK03...

07/09/2026

Oncology